Effects of statins on the risk of hepatocellular carcinoma

Pejman G. Mansourian, Masato Yoneda, M. Krishna Rao, Fernando J. Martinez, Emmanuel Thomas, Eugene R. Schiff

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer morbidity and mortality worldwide and is one of the few cancers that is increasing in incidence. This cancer often arises in the setting of hepatic cirrhosis; however, it can also occur in patients with chronic hepatitis B virus infection without cirrhosis. Statins have been used for many years for the prevention and treatment of cardiovascular disease. Based on recent meta-analyses, these lipid-lowering agents are now being investigated for a class effect observed in the prevention of carcinogenesis. There are robust data suggesting that statins can alter biochemical pathways involved in tumorigenesis and cell survival and, thus, have a protective effect by reducing the risk of development of several types of cancer. In recent years, several studies have demonstrated that statins also can specifically decrease the risk of HCC development. Because statins are underutilized in patients with preexisting liver disease, understanding the role of statins in the prevention of HCC is important, and changes in practice guidelines supporting the use of statins as chemoprotective agents may be warranted.

Original languageEnglish (US)
Pages (from-to)417-426
Number of pages10
JournalGastroenterology and Hepatology
Volume10
Issue number7
StatePublished - Jul 2014

    Fingerprint

Keywords

  • Cirrhosis
  • Hepatitis B
  • Hepatitis C
  • Hepatocellular carcinoma
  • HMG-CoA reductase
  • Nonalcoholic steatohepatitis
  • Statins

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Mansourian, P. G., Yoneda, M., Rao, M. K., Martinez, F. J., Thomas, E., & Schiff, E. R. (2014). Effects of statins on the risk of hepatocellular carcinoma. Gastroenterology and Hepatology, 10(7), 417-426.